Trial: 201912018

A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Phase

III

Principal Investigator

Cluster, Andrew

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov